A Phase 4 clinical trial involving abaloparatide has been updated as of June 8, 2026. The trial, registered as NCT04467983 and titled "Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone," is currently listed with a status of active, not recruiting.
This study is designed to compare adding abaloparatide to an ongoing denosumab regimen against continuing denosumab alone. As a Phase 4 trial, it falls under post-approval research categories.
The status update indicates that enrollment for this trial is not currently open to new participants, though the study remains active. No results or outcome data have been reported as part of this update.
Abaloparatide itself is an approved compound. This particular trial update reflects only the current recruitment and active status of the study as registered on ClinicalTrials.gov. No efficacy or safety conclusions can be drawn from a status change alone.
Further details about the trial design, objectives, and eventual results can be found through the official ClinicalTrials.gov listing. Readers interested in learning more about abaloparatide in general can refer to the compound overview for additional context.